Nicolas Guisot

Background

About Nicolas Guisot

Experienced project leader with more than 15 years of experience in small-molecule drug discovery and clinical development across multiple therapeutic areas (oncology, inflammation and fibrosis) and various target classes (enzymes, kinases, ion channels).Track record of delivering multiple projects from early exploratory science through to clinical development including the discovery of marketed BTK reversible inhibitor Jaypirca (Pirtobrutinib, LOXO-305, RXC005) and RXC007, a ROCK2 selective inhibitor currently in Phase 2a in IPF.Expert in the fields of medicinal chemistry, CMC and ADMET from hit finding to IND-enabling studies, translational science, IP assessment and early clinical development.Leadership and management of programs from hit finding to IND-enabling studies including lead chemistry and project leader roles for both internal and external FTEs.Highly collaborative innovator of data-driven and structure-based medicinal chemistry design strategies with expertise across multiple areas of drug discovery that include cell biology, pharmacology, pharmacokinetics, pharmaceutical sciences, toxicology and intellectual property.Significant managerial, leadership and supervisory experience, leading medium to large project teams up to clinical candidate selection, working in multidisciplinary project teams. Experienced project leader with exemplary communication, decision-making, strategic and operational skills.Specialties: medicinal chemistry, leadership, structure based design, ligand based in-silico lead identification, property based design, hit finding, hit-to-lead, lead optimization, candidate selection, IND-enabling studies, outsourcing (chemistry and DMPK).